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Protein phosphatase 1-dependent bidirectional synaptic plasticity
controls ischemic recovery in the adult brain
Abstract
Protein kinases and phosphatases can alter the impact of excitotoxicity resulting from ischemia by
concurrently modulating apoptotic/ survival pathways. Here, we show that protein phosphatase 1 (PP1),
known to constrain neuronal signaling and synaptic strength (Mansuy et al., 1998; Morishita et al.,
2001), critically regulates neuroprotective pathways in the adult brain. When PP1 is inhibited
pharmacologically or genetically, recovery from oxygen/glucose deprivation (OGD) in vitro, or
ischemia in vivo is impaired. Furthermore, in vitro, inducing LTP shortly before OGD similarly impairs
recovery, an effect that correlates with strong PP1 inhibition. Conversely, inducing LTD
beforeOGDelicits full recovery by preserving PP1 activity, an effect that is abolished by PP1 inhibition.
The mechanisms of action of PP1 appear to be coupled with several components of apoptotic pathways,
in particular ERK1/2 (extracellular signal-regulated kinase 1/2) whose activation is increased by PP1
inhibition both in vitro and in vivo. Together, these results reveal that the mechanisms of recovery in the
adult brain critically involve PP1, and highlight a novel physiological function for long-term
potentiation and long-term depression in the control of brain damage and repair.
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Protein kinases and phosphatases can alter the impact of excitotoxicity resulting from ischemia by concurrently modulating apoptotic/
survival pathways. Here, we show that protein phosphatase 1 (PP1), known to constrain neuronal signaling and synaptic strength
(Mansuy et al., 1998; Morishita et al., 2001), critically regulates neuroprotective pathways in the adult brain. When PP1 is inhibited
pharmacologically or genetically, recovery fromoxygen/glucosedeprivation (OGD) in vitro, or ischemia in vivo is impaired. Furthermore,
in vitro, inducing LTP shortly before OGD similarly impairs recovery, an effect that correlates with strong PP1 inhibition. Conversely,
inducing LTDbeforeOGDelicits full recovery by preserving PP1 activity, an effect that is abolished byPP1 inhibition. Themechanisms of
action of PP1 appear to be coupled with several components of apoptotic pathways, in particular ERK1/2 (extracellular signal-regulated
kinase 1/2) whose activation is increased by PP1 inhibition both in vitro and in vivo. Together, these results reveal that the mechanisms
of recovery in the adult brain critically involvePP1, andhighlight anovel physiological function for long-termpotentiation and long-term
depression in the control of brain damage and repair.
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Introduction
Cerebral ischemia often leads to neural damage resulting from
transient deprivation of oxygen and nutrients in the brain. Such
deprivation causes a dramatic increase in neuronal excitation
caused by enhanced glutamate release and a toxic rise in intracel-
lular calcium (Ca2) (Olney and Sharpe, 1969; Arundine and
Tymianski, 2004). Affected regions of the brain are often irrevers-
ibly injured and show long-lasting functional impairments. Be-
cause ischemia is highly detrimental to brain functions, much
work has been done to better understand the underlying molec-
ular mechanisms and to develop neuroprotective therapies. The
limited success of glutamate receptor (NMDA or AMPA) antag-
onists in the clinic (Aarts and Tymianski, 2003) has, however,
prompted interest in the intracellular pathways downstream
from glutamate receptors, with the hope that their study would
bring potential therapeutic insight (Legos et al., 2002; Aarts and
Tymianski, 2003).
Ca2 overload during ischemic insult dramatically alters
Ca2-dependent signaling and buffering systems (Lipton, 1999;
Sattler and Tymianski, 2000; Arundine and Tymianski, 2003;
Sugawara et al., 2004) and perturbs the activity of Ca2-
dependent protein kinases and phosphatases. Such alteration
strongly impacts the outcome of excitotoxicity. Thus, an imbal-
ance between the activity of the Ca2-dependent protein kinase
II (CaMKII), protein kinase C (PKC) (Onodera et al., 1995;
Aronowski et al., 2000), and the protein phosphatase calcineurin
(CaN or PP2B) in favor of CaN, induces an excessive dephos-
phorylation of proapoptotic proteins (Asai et al., 1999; Wang et
al., 1999) and leads to delayed neuronal death. In contrast, inhi-
bition of CaN by the immunosuppressants FK506 (Fujimycin) or
cyclosporine A prevents neuronal degeneration, reduces infarct
size, and rescues motor functions after experimental stroke in rat
(Sharkey and Butcher, 1994; Sharkey et al., 1996; Morioka et al.,
1999). These results therefore indicate that CaNhas both apopto-
tic and neuroprotective functions thatmay depend on the nature,
kinetics, and extent of the injury.
Unlike CaN, the functions of other brain protein phospha-
tases in cerebral ischemia remainmostly unknown. In particular,
the role of protein phosphatase 1 (PP1), the second most abun-
dant protein serine/threonine phosphatase in the brain, has not
been extensively examined in the context of brain injury. A few
reports in culture systems, however, have suggested that PP1may
have neuroprotective functions (Fernandez et al., 1993; Nuydens
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et al., 1998; Runden et al., 1998; Klumpp andKrieglstein, 2002; Yi
et al., 2005). To examine the potential functions of PP1 in the
mechanisms of recovery, we used in vitro and in vivo models of
ischemia in the adult mouse brain, and tested the effect of a
change in PP1 activity on recovery. Pharmacological, genetic, and
electrophysiologicalmethods were used to inhibit or activate PP1
in vitro and in vivo, and recovery was evaluated after oxygen/
glucose deprivation (OGD) in hippocampal slices or focalmiddle
cerebral artery occlusion (MCAO) in adult mice. Our results
demonstrate that PP1 andPP1-dependent bidirectional plasticity
control the mechanisms of recovery in the adult brain, and that
PP1 involves downstream components of apoptotic and cell sur-
vival pathways, in particular extracellular signal-regulated kinase
1/2 (ERK1/2), both in vitro and in vivo.
Materials andMethods
Animals. Adult C57BL/6J mice or I-1* mutant and control littermates
(9–12 weeks of age) were used. I-1* mice were obtained as previously
described (Genoux et al., 2002) and were backcrossed to the C57BL/6J
background for at least 8–10 generations. Mutant mice carry the
CaMKII promoter-rtTA(2) and tetO-I-1* transgenes, and controlmice
are littermates carrying no transgene or either one of the transgenes.Mice
were fed with 6 mg/g doxycycline (Westward Pharmaceuticals, Eaton-
town,NJ)mixedwithwet food (50:50 food-to-water ratio) for at least 7 d
before experiments. All experiments were performed in accordance with
Swiss Federal Veterinary Office regulations and by experimenters blind
to genotype.
Electrophysiological recordings. Adult mice were killed by cervical dis-
location, and heads were immediately immersed for at least 3 min in
freshly prepared ice-cold oxygenated artificial CSF (aCSF) (119 mM
NaCl, 11 mM D-glucose, 1.3 mMMgCl26H2O, 1.3 mMNaH2PO4, 2.5 mM
KCl, 2.5 mM CaCl2, 26 mM NaHCO3, gassed for a minimum of 20 min
before use and throughout experiment with 95% O2/5% CO2). Brains
were quickly removed, and hippocampi were dissected. Acute slices (400
m thick) were prepared with a vibratome (VT 1000S; Leica, Nussloch,
Germany) in ice-cold oxygenated aCSF. Slices were transferred to an
interface chamber at 34°C for 40–50 min, and then kept at room tem-
perature for at least 1–2 h before recording. Recordings were performed
at 27–28°C in a submersion chamber (Slice Mini Chamber III/IV; Luigs
& Neumann, Ratingen, Germany) continuously perfused with oxygen-
ated aCSF at 1.1 ml/min. A monopolar electrode was placed in the stra-
tum radiatum to activate Schaffer collaterals and test stimuli were applied
at 0.033 Hz at an intensity set to evoke one-third to one-half of the
maximum field EPSP (f-EPSP). Evoked f-EPSPs were recorded in the
stratum radiatumwith a borosilicatemicropipette filled with 3 MNaCl or
aCSF. Signals were amplified with an AXOPATCH 200B amplifier (Mo-
lecular Devices, Palo Alto, CA) and sampled using pCLAMP. Baseline
responses were recorded until stable for at least 10 min.
OGD. Acute slices (hippocampus, cortex, and striatum) were exposed
to 15 to 25 min of hypoxic/aglycemic conditions by perfusion with aCSF
containing no glucose (replacedwith equimolar sucrose) and gassedwith
N2/CO2 (95%/5%). Shorter OGD (15 min) was applied in slices when
0 mV f-EPSP was reached before 25 min incubation. The results from
these experiments were not statistically different from those obtained
with 25 min OGD and were therefore pooled for final analyses. OGD
solution reached the recording chamber within 30 s and replaced entirely
the normoxic aCSF within 2–3 min.
Long-term potentiation/long-term depression. Long-term potentiation
(LTP) was induced by a 1 s train at 100 Hz, and long-term depression
(LTD) by 10 min paired pulse stimulation at 2 Hz with 200 ms inter-
stimuli interval, applied to the Schaffer collaterals. In experiments com-
bining LTP or LTD with OGD, normoxic aCSF was replaced with OGD
aCSF 10 min after the end of LTP or LTD induction. Two-pathway
experiments were performed by placing stimulating electrodes in stra-
tum radiatum on either side of the recording electrode. Alternating test
stimuli were given every 15 or 7.5 s for LTP or LTD experiments, respec-
tively. High-frequency stimuli (HFS) or low-frequency stimuli (LFS)
were applied on alternating electrodes to ensure that both pathways
could be modulated. Conditioning stimuli were delivered to both path-
ways in slices used for the phosphatase assay.
Treatment and drugs.Drugs for slice recordings were bath-applied for
2 h before recording in oxygenated aCSF. Okadaic acid (OA) (Alexis
Corporation, Lausen, Switzerland) and tautomycin (Alexis Corporation;
Sigma, Buchs, Switzerland) were dissolved in DMSO (30mM) andmeth-
anol or ethanol (1 mM), respectively, and stock solutions were diluted
further in aCSF the day of the experiment. The respective vehicles were
used for drug-control experiments. For both mutant and control slices,
aCSF was supplemented with doxycycline hydrochloride (Sigma) at 8
ng/ml and kept protected from direct light illumination.
Phosphatase assay. Hippocampal slices were stimulated on two path-
ways with HFS or LFS 10 min before OGD as described above. CA1 was
dissected either immediately (OGD 0min) or 1 h (OGD 1 h) after OGD,
homogenized in buffer [3.75 mM Tris-HCl, pH 7.4, 15 mM KCl, 3.75 mM
NaCl, 250 M EDTA, 50 M EGTA, 30% (v/v) glycerol, 15 mM
-mercaptoethanol, protease inhibitor mixture (Sigma), 100 M PMSF]
using a 26 gauge syringe, and frozen on dry ice or in liquid nitrogen.
Phosphatase activity was determined by incubating 2 g sample with
0.15 mM RII phosphopeptide substrate and 5 nM tautomycin (for PP1
activity) or 5 nM tautomycin/5 nM OA (for PP1 and PP2A activity) in
buffer containing 50 mM Tris-HCl, pH 7.0, 100 M Na2EDTA, 5 mM
DTT, and 0.01% Brij 35 at 30°C for 10 min. RII is a phosphopeptide
derived from the regulatory subunit of PKA (protein kinase A) that is
phosphorylated on serine residues and thus can be dephosphorylated by
any of the serine/threonine phosphatases. The specificity of themeasure-
ment of PP1 and PP2A activity relies on the specificity of the pharmaco-
logical phosphatase inhibitors, tautomycin and okadaic acid (do not in-
hibit PP2C) at defined doses. The reaction was terminated by addition of
TCA and centrifugation at 13,000  g for 5 min. The amount of free
phosphates released in the reaction was measured by mixing the super-
natant with Biomol Green reagent (Biomol, PlymouthMeeting, PA) and
color density was detected at OD620. For determining total phosphatase
activity, tautomycin and OA were removed from the reaction. Back-
ground activity was measured separately in a reaction without RII sub-
strate and in a reaction without sample. The percentage phosphatase
activity was calculated by subtracting the background from the total and
inhibited reactions, and then dividing the inhibited activity by the total
activity.
Intraluminal MCAO. Adult I-1* mutant and control littermates
(21–28 g) were anesthetized with isoflurane and subjected to focal cere-
bral ischemia by intraluminal MCAO using an 8-0 silicon-coated (Xan-
topren; Bayer Dental, Osaka, Japan) nylonmonofilament (Ethilon; Ethi-
con, Norderstedt, Germany). Laser Doppler flow was monitored using a
flexible 0.5mmfiberoptic probe (Perimed, Stockholm, Sweden) attached
to the intact skull overlying the middle cerebral artery territory. Rectal
temperature was maintained at 36.5–37.0°C with a feedback-controlled
heating system. After MCAO, wounds were carefully sutured and anes-
thesia was discontinued. After 24 h (90 min MCAO) or 72 h (30 min
MCAO) of reperfusion, animals were anesthetized with isoflurane and
killed. Brainwas removed and either frozen ondry ice and cut into 18m
cryostat sections or dissected out bilaterally for Western blot analyses.
Histology. Brain sections from animals subjected to 90 min of MCAO
were fixed in 4%paraformaldehyde/0.1 M PBS and infarct volumetry was
performed after cresyl violet staining. Five sections from equidistant
brain levels (2 mm apart) were evaluated for each animal. Borders be-
tween infarcted and noninfarcted tissue were outlined using an image
analysis system (Image J) (Spudich et al., 2006) by an investigator blind to
genotype outlining the unaffected (i.e., healthy tissue on both sides of the
brain), fromwhich the difference value was calculated, which reflects the
edema-corrected infarct area on a particular brain level. The infarct areas
from all levels of the brain (n 4) were finally integrated over the whole
brain for determining infarct volume. In animals undergoing 30 min
MCAO, section from the bregma level were stained by terminal deoxy-
nucleotidyl transferase-mediated biotinylated UTP nick end labeling
(TUNEL) using a kit (Roche, Basel, Switzerland). The number of DNA
fragmented cells in the striatumwas quantified by a stereologicalmethod
using uniform random sampling of an array with six regions of interest
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(250  250 m per area) separated by 250 m, for which mean values
were calculated to determine the number of irreversibly injured cells as
previously described (Hermann et al., 2001).
Western blots. Tissue samples from the striatum ipsilateral and con-
tralateral toMCAOor from acute forebrain slices (hippocampus, cortex,
and striatum) were homogenized and centrifuged. Supernatants were
resolved on SDS-PAGE, and proteins were transferred onto polyvinyli-
dene difluoride membranes. Membranes were dried and incubated in
blocking solution, and then in rabbit anti-ERK1/2 (9102; Cell Signaling,
Beverly, MA), mouse anti-phospho-ERK1/2 (anti-phospho-Thr and
Tyr, M8159; Sigma), rabbit anti-c-Jun N-terminal kinase 1/2 (JNK1/2)
(JNK2; sc-572; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
phospho-JNK1/2 (anti-Tyr185, 9251; Cell Signaling), rabbit anti-Bcl-X
(610212; BD Biosciences, Mountain View, CA), or rabbit anti-activated
caspase-3 (CM1; BD Biosciences) antibody (1:500 in 0.1% Tween 20, 0.1
M TBS) (Kilic et al., 2005). Membranes were rinsed, incubated in
peroxidase-coupled secondary antibody (1:2000 in 0.1%Tween 20, 0.1 M
TBS), washed, immersed in enhanced chemoluminescence (ECL) solu-
tion, and then exposed to ECL-Hyperfilm (Amersham Biosciences, Pis-
cataway, NJ). The band intensity was determined by densitometry and
corrected for protein loading using anti--actin antibody (A5316;
Sigma) as an internal control.
Data analysis. For each electrophysiological experiment, the average
slope of individual f-EPSP was measured from the initial 1–1.5 ms por-
tion after the fiber volley using Clampfit (Molecular Devices). For statis-
tical analyses, the f-EPSP slope was averaged over 1 min and analyzed by
three-way ANOVAusing Statview 5.0 with sequences (10min) and stim-
ulation (1 min bins) as repeated measures. The between-subjects factors
were OA doses (control vs 0.1 nM, 1 nM, or 1 M), tautomycin doses
(control vs 1, 5, 10, or 100 nM), genotype (controls vs mutants), delay
between LTP or LTD and OGD (controls vs 10 or 30 min), genotype on
LTD and LTDplusOGD (controls vsmutants) and combined genotype–
drug treatment on LTD and LTD plus OGD (controls vs mutant plus
tautomycin). Unpaired t tests were performed on mean f-EPSP for 10
min toward the end of recording as indicated inResults, whenmain effect
of between-subjects factor reached significance. In some cases, the gen-
eralized linear model followed by Tukey’s or least significant difference
(LSD) post hoc tests were used to evaluate electrophysiological or phos-
phatase assays data. Infarct volume and DNA fragmentation were ana-
lyzed by two-tailed t tests. Western blots were evaluated by one-way
ANOVA followed by LSD post hoc tests. Statistical significance was set at
p 0.05, and data are presented as mean SEM.
Results
Pharmacological and genetic inhibition of PP1 reduces
recovery fromOGD in acute hippocampal slices
To examine the role of PP1 in the mechanisms of recovery from
ischemic injury, we simulated conditions of transient cerebral
ischemia in vitro by exposing acute hippocampal slices fromadult
mouse brain to OGD. Unlike long-term deprivation that causes
irreversible cell death, transientOGD inducesmild and reversible
damage such as decreased metabolic activity (Lushnikova et al.,
2004), inhibition of transmitter release (Fowler, 1989), and in-
creased postsynaptic Ca2 influx, spontaneous miniature EPSC
amplitude, evoked AMPA andNMDA receptor-mediated excita-
tory responses, and AMPA/NMDA responses ratio (Quintana et
al., 2006). The impact of OGD was evaluated by measuring
f-EPSPs evoked in area CA1 by electrical stimulation of Schaffer
collaterals (Raley-Susman and Lipton, 1990; Lobner and Lipton,
1993).OGD induced a rapid decline of the f-EPSP slope, followed
by a partial recovery, and then a slow stabilization to, however, a
level that was significantly lower than baseline. These results in-
dicate that OGD induces long-lasting cellular changes that de-
crease f-EPSP and are indicative of damaged neuronal functions
(Fig. 1A, solid circles). We then examined the impact of PP1
inhibition before OGD using pharmacological, genetic, and
physiological means on recovery. First, tautomycin, a highly se-
lective PP1 inhibitor (IC50 for PP1, 1.1–7.5 nM; for PP2A, 10–23
nM) was applied to slices before OGD, at a dose ranging from 1 to
100 nM to inhibit either PP1 alone (low concentration) or both
PP1 and PP2A (high concentration). A significant dose-
dependent reduction in f-EPSP recovery was observed (dose ef-
fect, F(5,20) 139.8, p 0.001) (Fig. 1A), which had an IC50 of 2.4
nM (95% confidence, 2.2–2.7 nM) (Fig. 1B), strongly suggesting
that it wasmediated by PP1 inhibition (IC50 10 nM) and not by
PP2A inhibition [IC50 10 nM (Gupta et al., 1997)]. To confirm
these results, we used OA (0.1 nM to 1 M), another protein
phosphatase inhibitor 50-fold more selective for PP2A than PP1
[IC50 for PP2A, 0.02–1.0 nM; for PP1, 10–1300 nM (Gupta et al.,
1997)]. We reasoned that, if the effect of tautomycin is attribut-
able to PP1 inhibition, low doses of OA that only inhibit PP2A
should not reduce f-EPSP recovery after OGD. Consistent with
this hypothesis, only high doses of OA had an effect on f-EPSP
recovery. f-EPSP recovery was significantly reduced at 1 M OA
but not at 1 nM, a concentration insufficient to inhibit PP1 (dose
effect, p  0.05) (Fig. 1C; supplemental Fig. 1A, available at
www.jneurosci.org as supplemental material). The IC50 for this
effect was 53 nM (95% confidence, 64.3 pM to 54.7 M) (supple-
mental Fig. 1B, available at www.jneurosci.org as supplemental
material), again suggesting a PP1-dependent f-EPSP recovery.
To confirm the PP1 dependence of the effect and delineate the
cell type specificity of the functions of PP1, we used transgenic
mice in which PP1 is selectively inhibited in forebrain neurons
(to 67.7 12%) by expression of a constitutively active form of
the PP1 inhibitor, inhibitor-1 (I-1*) (Genoux et al., 2002;Micha-
lon et al., 2005). Consistent with the reduced recovery observed
with tautomycin and OA, I-1*-mediated PP1 inhibition in the
hippocampus significantly diminished f-EPSP recovery after
OGD in transgenic slices (Fig. 1D). This effect was not attribut-
able to a change in basal synaptic transmission, whichwas normal
in transgenic slices (Jouvenceau et al., 2006). These results there-
fore confirm that suppression of recovery is attributable to PP1
inhibition, and indicate that the effect can be induced by selective
inhibition of PP1 in neuronal cells.
Induction of LTP before OGDmimics the effect of
PP1 inhibition
We next evaluated whether a change in PP1 activity induced by
physiological stimulation can also modulate f-EPSP recovery af-
terOGD. Previous studies have suggested that long-term changes
in synaptic transmission are associatedwith alterations in protein
phosphatase activity. Specifically, PP1 and PP2A activity is tran-
siently inactivated shortly after induction of LTP but is activated
shortly after induction of LTD (Winder and Sweatt, 2001).
Therefore, we used LTP to attempt to decrease PP1 activity in
area CA1 before OGD by stimulating Schaffer collaterals with a
high-frequency tetanus (HFS; 100 Hz, 1 s) in wild-type slices
(LTP) (Fig. 1E). After LTP andOGD, f-EPSP slope decreased but
recovered to a level that was significantly lower than in slices not
subjected to LTP (42.3 2.9%) (Fig. 1E). This effect was specific
to the potentiated synapses because simultaneous two-pathway
recordings showed normal f-EPSP recovery in an adjacent non-
tetanized pathway (no LTP) (Fig. 1E, inset). We confirmed that
the effect of LTP on recovery was associated with a change in PP1
activity bymeasuring PP1 and PP2A activity in slices subjected to
LTP, both immediately (0 min) and 1 h (1 h) after OGD. OGD
itself was found to rapidly diminish PP1 activity (no LTP after 1 h,
56.4  12.4% inhibition from basal) (Fig. 1F). However, when
LTP was induced before OGD, PP1 activity was decreased signif-
icantly more than without LTP 1 h after OGD. The decrease in
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f-EPSP recovery was again specific to PP1 because PP2A, also
inhibited byOGD alone, was not further inhibited by LTP induc-
tion (Fig. 1G).
Induction of LTD before OGD promotes recovery
We then tested the effect of LTD induction on f-EPSP recovery.
Remarkably, in contrast to LTP, LTD induction led to a full re-
covery of f-EPSP, which, after OGD, reached a level comparable
with that in slices subjected to LTD without OGD (Fig. 2A).
Two-pathway recordings confirmed that the beneficial effect of
LTD was specific to depressed synapses (Fig. 2A, inset). Fur-
thermore, it was accompanied by full restoration of PP1 activ-
ity 1 h after OGD, an effect that was not observed in the
absence of LTD (Fig. 2B). It was specific to PP1, because PP2A
activity was not significantly changed by LTD induction (Fig.
2C). To confirm that the full recovery of f-EPSP induced by
LTD is mediated by PP1, we repeated the experiment in hip-
pocampal slices from I-1* transgenic mice. In these slices,
partial inhibition of PP1 [67.7  12% (Genoux et al., 2002)]
did not abolish the beneficial effect of LTD on f-EPSP recovery
(Fig. 2D, LTD mutants), most likely because of the residual
PP1 activity not fully inhibited by I-1* expression. Consistent
with this hypothesis, blockade of this residual activity by a
suboptimal dose of tautomycin (1 nM) fully abolished the ben-
eficial effect of LTD on f-EPSP recovery (Fig. 2D, LTD mu-
tant/tautomycin). This dose of tautomycin had no effect on
LTD in control slices (Fig. 2E, inset) but abolished LTD in I-1*
slices (Fig. 2E). These results highlight a neuroprotective role
for LTD through PP1-dependent mechanisms.
Genetic inhibition of PP1 aggravates injury after focal
cerebral ischemia in vivo and involves ERK-dependent
pathways
To validate our findings in vivo, we next examined whether the
genetic inhibition of PP1 in adult mice affects the extent of dam-
age after ischemia. I-1* transgenic mice and control littermates
were subjected to intraluminal MCAO, and the effect on brain
tissue was evaluated 24 h later. Consistent with our findings in
vitro, PP1 inhibition significantly enlarged infarct volume in I-1*
mutantmice (Fig. 3A,B) and increased TUNEL staining, indicat-
ing a larger number of cells undergoing cell death (Fig. 3D,E).
This effect was not attributable to impaired blood circulation
because Doppler flowmetry showed similar hemodynamic
changes in control and transgenic mice during MCAO (Fig.
3C,F). Because the degree of cell survival after ischemia depends
on the activation or suppression of apoptotic pathways, we next
Figure1. PP1 inhibition reduces f-EPSP recovery fromOGD.A, Tautomycin (TM) diminishes f-EPSP recovery after OGD in a dose-dependentmanner (F(5,20) 139.8; p 0.3).Mean f-EPSP slope
80–90min after the onset of OGD: 1nM, 88.61.5%,NS,n5; 3 nM, 31.44.6%,p0.001,n5; 10nM, 4.42.9%,p0.001,n3; 100nM, 0.91.3%,p0.001,n5; versus control
slices (n 4) 79.3 6.2%, p 0.01.B, IC50 for this effect is 2.4 nM (95% confidence, 2.2–2.7 nM). C, Dose-dependent reduction of f-EPSP (F(5,29) 3.54; p 0.05) after okadaic acid treatment.
After 80–90min, f-EPSP slope recovers up to 76.6 20.5%,NS, n 4 at 0.1 nM, 56.6 23.9%,NS, n 4 at 10 nM, and 20.3 14.4%, p 0.001, n 8 at 1M versus 0 nM control slices, 79.2
4.9%, p 0.005, n 10, **p 0.001 versus OGD. D, Genetic inhibition of PP1 in I-1*mutant mice reduces f-EPSP recovery after OGD down to 34.2 9.7% of baseline 90min after the onset of
OGD comparedwith 71.3 5.8% in control slices (mean effect of genotype, F(1,28) 11.81; p 0.005; controls, n 13;mutants, n 17). The inset shows representative traces before (1, 3) and
after (2, 4) OGD in control (1, 2) andmutant (3, 4) slices (scale: x, 2 ms; y, 0.8mV). E, LTP induced 10min before OGD reduces f-EPSP slope recovery in control hippocampal slices. Mean f-EPSP slope
(over the last 10 min of recording) in OGDwith no LTP (69.3 3.5%; n 33) is significantly different from LTP (40.6 13.7%; n 11) Tukey’s post hoc, p 0.005. Inset shows a two-pathway
experiment in which f-EPSP recovery is diminished only in potentiated synapses (no LTP pathway: 70.0 3.5%, n 4, versus LTP pathway: 37.5 3.5%, n 4, Tukey’s post hoc, p 0.001). F,
PP1 activity (percent total protein phosphatase activity) before OGD (white bar), and immediately (0 min) or 1 h (1 h) after OGD in slices not subjected to LTP (black bars) or preceded by LTP (gray
bars). OGD, 0min: F(3,44) 2.947, p 0.05; no LTP: 56.4 12.4% inhibition frombaseline, n 10, LSD post hoc, p 0.05; OGD 1 h: F(3,38) 14.98, p 0.001; No LTP: 52.9 15.9% inhibition
from baseline, n 8, Tukey’s post hoc, p 0.05; and LTP/OGD 1 h: 99.5 17.0% inhibition from baseline, n 9, Tukey’s post hoc, p 0.001 compared with baseline, LSD post hoc, p 0.05
compared with no LTP OGD 1 h. Statistical significance compared with baseline: †p 0.05, ††p 0.01, †††p 0.001; compared with no LTP: *p 0.05. G, PP2A activity is not altered by LTP
induced before OGD (OGD 0 min: no LTP, 4.5 3.1, n 7; LTP, 6.1 7.6, n 6, vs OGD 1 h: no LTP, 11.5 4.4%, n 7; LTP, 17.2 3.9%). Black bars, No LTP; gray bars, subjected to LTP.
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examined whether major apoptotic pro-
cesses are associated with the detrimental
effect of PP1 inhibition.Western blot anal-
yses revealed that the phosphorylation
level of ERK1, ERK2, and JNK2, cytoplas-
mic signaling molecules involved in
ischemia-induced cell death (Bogoyevitch
et al., 2004; Chu et al., 2004) (but see Het-
man and Gozdz, 2004), were significantly
increased by PP1 inhibition in vivo (Fig.
4A,C). Remarkably, after MCAO, phos-
phorylated ERK1 and ERK2 were further
increased in I-1*mutantmice (Fig. 4A,C).
Importantly, this effect was confirmed in
vitro after OGD and PP1 inhibition (Fig.
4B), indicating that similar mechanisms
are recruited in vivo and in vitro. The con-
sistency of these results strongly suggests
that ERK1/2 activation is regulated by PP1
during an ischemic insult and that PP1
converges onto similar cell survival/death
pathway in both models. Finally, de-
creased expression of the antiapoptotic
protein Bcl-XL and activation of the apo-
ptotic protease caspase-3 induced by
MCAO were accentuated by genetic inhi-
bition of PP1 in vivo (Fig. 4E,F), pointing
to the potential involvement of these op-
posing pathways in PP1-dependent
mechanisms.
Discussion
The present results provide evidence that
the serine/threonine protein phosphatase
PP1 and PP1-dependent bidirectional
plasticity are critical for themechanisms of
recovery from excitotoxicity in the adult
mouse brain. These results demonstrate
that a decrease in PP1 activity induced by
pharmacological or genetic inhibition be-
fore OGD in hippocampal slices or before
MCAO in vivo, alters the mechanisms of recovery. Furthermore,
in vitro f-EPSP recovery, a parameter affected by cellular damage,
is impaired when LTP is induced before OGD, an effect that is
associatedwith selective inhibition of PP1. In contrast, the induc-
tion of LTD before OGD promotes full f-EPSP recovery and is
associated with restoration of PP1 activity after OGD. Consis-
tently, the beneficial effect of LTD is abolished by blockade of PP1
activity. These results confirm that recovery from OGD involves
PP1-dependent pathways and indicate that modulation of recov-
ery by synaptic plasticity is associated with direct changes in PP1
activity. Several targets of apoptotic and cell survival pathways
are involved in the detrimental effect of PP1 inhibition on
ischemic injury. PP1 inhibition is accompanied by increased
phosphorylation of ERK1/2 both in vitro and in vivo, and in-
creased JNK2 phosphorylation, caspase-3 activation, and de-
creased Bcl-XL expression in vivo. Together, these findings
reveal a novel molecular mechanism for brain recovery that
depends on PP1 and highlight a yet-unknown function for
LTP and LTD in regulating the brain response to injury.
Protein serine/threonine phosphatases have been sug-
gested to promote neuroprotection (Fernandez et al., 1993;
Nuydens et al., 1998; Runden et al., 1998; Klumpp and Kriegl-
stein, 2002; Stevens et al., 2003; Yi et al., 2005), but the specific
involvement of PP1 could not be examined until now because
of the limited specificity of pharmacological inhibitors and the
lack of selective activators of PP1. The only finding specific for
PP1 after ischemia showed rather contradictory results reveal-
ing increased PP1 and PP1mRNA in the hippocampal CA1
region and the striatum, but decreased PP1 protein and no
change in PP1 (Horiguchi et al., 2002). In the present study,
the combination of pharmacological, genetic, and physiolog-
ical methods allowed us to specifically manipulate PP1 activity
before experimental ischemia both in vitro and in vivo, and
demonstrate that PP1 is involved in the mechanisms of recov-
ery from excitotoxicity. Our manipulation further provided
new evidence that ERK1/2 expression and phosphorylation
are regulated by PP1 during an ischemic insult, both in vitro
and in vivo. Many reports using models of cerebral ischemia,
brain trauma, or neurodegenerative diseases have demon-
strated a detrimental role for ERK1/2 and JNK1/2 signaling
(Irving and Bamford, 2002; Bogoyevitch et al., 2004; Chu et al.,
2004). However, ERK1/2 has also been shown to be neuropro-
tective, suggesting that the function of ERK1/2 may depend on
the nature, duration, and severity of injury, cell type, and brain
area, or timing of analysis (Hetman and Gozdz, 2004). In the
Figure 2. LTD induction before OGD improves f-EPSP recovery through PP1-dependent mechanisms. A, LTD induced 10
min before OGD enhances f-EPSP slope recovery in control hippocampal slices. Mean f-EPSPmeasured 80 –90min after LFS
for LTD alone: 84.7 1.4% of baseline, n 6, versus LTD before OGD: 85.6 7.7% of baseline, n 6, and OGD alone (No
LTP  OGD): 70.9  5.21%, n  6. The inset shows a two-pathway experiment demonstrating that only depressed
synapses had full f-EPSP recovery (no LTD pathway: 76.9 1.0%, n 4, vs LTD pathway: 89.3 1.2%, n 4, Tukey’s
post hoc, p 0.001). B, PP1 is inhibited immediately (0 min, 56.4 12.4%) and 1 h (1 h, 52.9 15.9%) after OGD
comparedwith baseline (white bar); LSD post hoc, †p 0.05, versus slices not subjected to LTD (No LTD). In contrast, when
preceded by LTD, PP1 activity is inhibited to 70.5  22.5% of baseline immediately after OGD versus 2.0  8.1%
inhibition from baseline, n 5; Tukey’s post hoc, p 1.0, 1 h after OGD. Post hoc compared with no LTD, *p 0.05. Black
bars, No LTD; gray bars, subjected to LTD. C, Measure of PP2A activity showing that the effect of LTD is specific to PP1 and
does not involve PP2A (OGD 0 min: no LTD, 4.5 3.1%, n 7; LTD, 7.3 1.7%, n 5; OGD 1 h: no LTD, 11.5 4.4%,
n 7; LTD, 19.8 3.5%). White bar, Baseline; black bars, no LTP; gray bars, subjected to LTP. D, The enhanced f-EPSP
recovery because of LTD is reversed by full inhibition of PP1. LTD before OGD induces full recovery of f-EPSP in mutant slices
(LTD mutants, 85.4 3.8% of baseline at 90 min, n 7, vs control slices, 70.9 5.21%; n 6; unpaired t test, t(11)
3.12; p 0.05). Mutant slices pretreated with tautomycin (LTD mutant/TM) recover to 37.0 10.8% versus LTD mutant:
t test, t(10) 4.24, p 0.005. E, LTD in mutant slices can be abolished by a suboptimal dose of tautomycin: 96.3 3.6%
versus 87.6 4.6% of baseline in mutant slices (no drug, t(10) 3.12; p 0.05; n 6). The inset shows that this dose
of tautomycin has no effect on LTD in control slices.
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postischemic brain, the level of phosphorylated, activated
ERK1/2 and JNKs was reported to rapidly increase (Farrokh-
nia et al., 2005; Shackelford and Yeh, 2006), and inhibition of
ERK1/2 or JNKs suppresses neuronal injury after transient or
permanent MCAO in the rat (Alessandrini et al., 1999;
Borsello et al., 2003). However, the actual pathways linking the
initial steps of excitotoxicity to ERK/JNK activation and
apoptotic processes remain poorly understood.
Our results now provide evidence that PP1 is involved in the
regulation of ERK1/2 and JNK2 pathways and critically deter-
mines the response of neurons to excitotoxicity that engage these
pathways both in vitro and in vivo. This central function of PP1
suggests that it is strategically positioned upstream of major ap-
optotic/survival pathways, consistent with its ability to be re-
tained at the membrane near glutamate receptors through scaf-
folding proteins (Westphal et al., 1999). There, PP1 may couple
the NMDA receptor to downstream ERKs, JNKs, and apoptotic
pathways as suggested by our correlated data between PP1 activ-
ity, ERK1/2 phosphorylation and recovery. It may dephosphory-
late ERK1/2 directly (Quevedo et al., 2003) or indirectly possibly
by downregulating upstream MEKs such as reported in rat pitu-
itary cells (Manfroid et al., 2001). Furthermore, the simultaneous
increase in ERK1/2 and JNK2 phosphorylation induced by PP1
inhibition in vivo suggests that PP1 may, in addition, act to coor-
dinate ERK1/2 and JNK2 pathways. This highlights a yet-
unknown PP1-dependent cross talk between MAPK and JNK
pathways that may operate a few hours after injury (not observed
1 h after OGD in vitro). The ability of PP1 to associate with JNK2
in a tripartite complex inmitochondriamay underlie this feature,
and provide a means to tightly control this interaction (Brichese
et al., 2004). Moreover, the concomitant activation of ERK1/2
and JNK2may exacerbate the impact of excitotoxicity by activat-
ing the protease caspase-3. JNK1/2 activation is known to induce
the translocation of the proapoptotic protein Bax to mitochon-
dria. This operates by release of Bax from cytoplasmic seques-
tration and cleavage of procaspase-3 into activated caspase-3
(Guan et al., 2006). Caspase-3-mediated apoptosis was indeed
reported to be induced by PP1/PP2A inhibitors in several cell
types in culture (Fladmark et al., 1999). In turn, activated
caspase-3 may cleave antiapoptotic proteins such as Bcl-XL
and Bcl-2, both of which are known to associate with PP1
through the RVXF PP1-binding motif (Ayllon et al., 2000).
Thus, overall, the simultaneous upregulation of apoptotic
proteins and downregulation of antiapoptotic molecules in-
duced by PP1 inhibition in vivo indicate that PP1 has an im-
pact on multiple targets and pathways to limit excitotoxicity.
The consistent link between PP1 and ERK1/2 that we showed
both in vitro and in vivo also strongly suggests that the mech-
anisms of recovery in these two systems share dependence on
these two targets; however, it does not rule out the possibility
that additional mechanisms are also recruited.
Our findings that two major forms of synaptic plasticity in
vitro, LTP and LTD, modulate recovery from an OGD insult
reveal a novel physiological function for bidirectional hippocam-
pal plasticity in brain repair and damage. The correlation be-
tween their opposite effect on recovery and on PP1 activity
strongly indicates that both LTP and LTD operate through PP1-
dependent pathways to modulate recovery. These results there-
fore point to a pivotal role for PP1 not only in the control of
bidirectional plasticity such as previously demonstrated (Blitzer
et al., 1998; Morishita et al., 2001; Jouvenceau et al., 2006) but
also in the control of plasticity-dependent modulation of brain
recovery. This pivotal role may again derive from the strategic
positioning of PP1 in neuronal cells, in the vicinity of major
neurotransmitter receptor complexes such as the NMDA recep-
tor complex known to be critical for excitotoxicity (Lisman and
Zhabotinsky, 2001; Colbran, 2004; Mansuy and Shenolikar,
2006). Furthermore, the demonstration that LTP or LTD before
OGD is detrimental or beneficial to recovery suggests that previ-
ous activity at synapses has a strong influence on the response to
injury. This finding underscores the critical importance of the
state of plasticity of synaptic circuits at the time of insult, a notion
reminiscent ofmetaplasticity.Notably, a formof synaptic depres-
sion was previously suggested to enhance survival after transient
OGD in a population of hippocampal CA1 neurons in vivo
Figure 3. Genetic inhibition of PP1 aggravates brain infarct and disseminates neural
injury after MCAO. A, B, Representative cresyl violet staining of coronal brain sections (A)
and bar graph indicating mean infarct volume (B) 24 h after 90 min MCAO and reperfusion
in I-1* mutant mice and control littermates (two-tailed t test, p 0.05; n 8/group).
Scale bar, 2 mm. D, E, Representative TUNEL staining (D) and bar graph indicating mean
density of DNA-fragmented cells (E) in striatum 72 h after 30 min MCAO and reperfusion in
I-1*mutant mice and control littermates (two-tailed t test, p 0.05; n 6/group). Scale
bar, 100 m. C, F, Laser Doppler flowmetry during 90 min (C) or 30 min (F ) MCAO
followed by 30 min reperfusion indicating similar level of perfusion in I-1* mutant mice
and control littermates. *p 0.05.
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(Papas et al., 1993; Gao et al., 1998). In a similar preparation,
neurons more likely to die have been found to exhibit a form of
potentiation that may be similar to anoxic LTP reported in vitro
after short periods of OGD that may act as a prelude to injury
(Hori and Carpenter, 1994; Calabresi et al., 2003). These findings
corroborate our demonstration that LTP is neurotoxic and LTD
neuroprotective. However, it should also be noted that LTP has
been suggested to confer protection during preconditioning
when induced in between short episodes of hypoxia, through
mechanisms involving A1 adenosine receptors (Youssef et al.,
2001, 2003). However, in these studies, brief hypoxia was also
found to decrease synaptic responses (Youssef et al., 2001) and
downregulate Ca2 signaling, CaMKII, and PKC (Katsura et al.,
2001), which interfered with LTP induction, suggesting that neu-
roprotection may not directly derive from LTP itself (Youssef et
al., 2006). Finally, attenuation of kainic acid-induced neuronal
loss by LTP was also reported, suggesting that LTP may have
neuroprotective properties in certain conditions (Evans and
Wang, 2005).
Last, this study advances the understanding of the mecha-
nisms of damage and protection in the context of ischemia and
may provide new perspectives for the potential development of
treatment against brain pathologies such as ischemic stroke, trau-
matic brain injury, or some neurodegenerative disorders.
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